FDA Drug Approvals, Dermatology — 2019 Midyear Review

Mary L Windle, PharmD

Disclosures

August 05, 2019

Jeuveau (prabotulinumtoxinA-xvfs)

PrabotulinumtoxinA, an acetylcholine-release inhibitor and neuromuscular blocker, is indicated for temporary improvement in the appearance of moderate-to-severe glabellar facial lines associated with corrugator and/or procerus muscle activity in adults.

Approval was based on 2 randomized, multicenter, double-blind, placebo-controlled trials of identical design (N=654). At day 30, 67-71% of patients treated with prabotulinumtoxinA achieved grade 2 or higher improvement for the glabellar line scale from baseline at maximum frown, compared with 1% of those treated with placebo.[1,2]

Skyrizi (risankizumab)

Risankizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds to the p19 subunit of the human interleukin 23 (IL-23) cytokine and inhibits its interaction with the IL-23 receptor. It was approved in April 2019 for treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Approval was based on the UltlMMa-1 and UltlMMa-2 replicate phase 3, randomized, double-blind, placebo-controlled and active comparator–controlled international trials (N=997). Coprimary endpoints were proportions of patients achieving a 90% improvement in the Psoriasis Area Severity Index (PASI 90) and a static Physician's Global Assessment (sPGA) score of 0 or 1 at week 16 (nonresponder imputation). Risankizumab showed superior efficacy to both placebo and ustekinumab in the treatment of moderate-to-severe plaque psoriasis.

At week 16 of each study, PASI 90 was achieved by 74.8-75.3% patients receiving risankizumab, compared with 2-4.9% receiving placebo and 42-47.5% receiving ustekinumab (P <.0001 vs placebo and ustekinumab). Results from each trial for sPGA 0 or 1 at week 16 was achieved by 83.7-87.8% patients receiving risankizumab, compared with 5.1-7.8% receiving placebo and 61.6-63% receiving ustekinumab (P <.0001 vs placebo and ustekinumab).[3]

Other notable dermatology approvals

Dupixent (dupilumab) indication for atopic dermatitis was expanded to include adolescents aged 12 years or older.

Duobrii (halobetasol/tazarotene) is a new topical combination for adults with plaque psoriasis.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....